Evidence map›Paper›PMID 41330923›Full record

ArticleNature communications2025

Residual tumor cells after insufficient radiofrequency ablation promote lung metastasis by educating CD177

Na Huang, Yisheng Fang, Siting Zheng, Jianhua Wu, Genjie Huang, Xinyue Deng, Yijin Guan, Bishan Liang, Dongqiang Zeng, Beibei Xu and 8 more

Abstract read
In one paragraph

Article in Nature communications, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Review
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors.

Na Huang *Department of Oncology, Nanfang Hospital, Southern Medical University, Guangzhou, China.ORCID http://orcid.org/0000-0001-7961-0677
Yisheng Fang *Department of Oncology, Nanfang Hospital, Southern Medical University, Guangzhou, China.
Siting Zheng *Department of Oncology, Nanfang Hospital, Southern Medical University, Guangzhou, China.
Jianhua Wu *Department of Oncology, Nanfang Hospital, Southern Medical University, Guangzhou, China.ORCID http://orcid.org/0000-0003-4142-8903
Genjie HuangDepartment of Oncology, Nanfang Hospital, Southern Medical University, Guangzhou, China.ORCID http://orcid.org/0009-0001-7777-910X
Xinyue DengDepartment of Oncology, Nanfang Hospital, Southern Medical University, Guangzhou, China.
Yijin GuanDepartment of Oncology, Nanfang Hospital, Southern Medical University, Guangzhou, China.
Bishan LiangDepartment of Oncology, Nanfang Hospital, Southern Medical University, Guangzhou, China.
Dongqiang ZengDepartment of Oncology, Nanfang Hospital, Southern Medical University, Guangzhou, China.ORCID http://orcid.org/0000-0001-9724-8325
Beibei XuDepartment of Oncology, Nanfang Hospital, Southern Medical University, Guangzhou, China.
Yuanwen HuangDepartment of Oncology, Nanfang Hospital, Southern Medical University, Guangzhou, China.
Xiaoxiang RongDepartment of Oncology, Nanfang Hospital, Southern Medical University, Guangzhou, China.
Chunlin WangDepartment of Oncology, Nanfang Hospital, Southern Medical University, Guangzhou, China.
Jianping BinThe Sixth Affiliated Hospital, School of Medicine, South China University of Technology, Foshan, China.ORCID http://orcid.org/0000-0003-4799-1502
Yulin LiaoThe Sixth Affiliated Hospital, School of Medicine, South China University of Technology, Foshan, China.ORCID http://orcid.org/0000-0001-5961-390X
Zuqiang WuThe Sixth Affiliated Hospital, School of Medicine, South China University of Technology, Foshan, China. lywuzq@scut.edu.cn.ORCID http://orcid.org/0009-0005-1853-6860
Min ShiDepartment of Oncology, Nanfang Hospital, Southern Medical University, Guangzhou, China. nfyyshimin@163.com.ORCID http://orcid.org/0000-0003-0113-4089
Wangjun LiaoDepartment of Oncology, Nanfang Hospital, Southern Medical University, Guangzhou, China. nfyyliaowj@163.com.ORCID http://orcid.org/0000-0002-1364-8442

Funding

Guangzhou Municipal Science and Technology Project 202201011433Guangzhou Municipal Science and Technology Project 2023A04J2360Nanfang Hospital 2022J005National Natural Science Foundation of China (National Science Foundation of China) 82002555National Natural Science Foundation of China (National Science Foundation of China) 82173187National Natural Science Foundation of China (National Science Foundation of China) 82272635Natural Science Foundation of Guangdong Province (Guangdong Natural Science Foundation) 2021A1515011705
6 · The paper itself

Abstract

Radiofrequency ablation (RFA) has been one of the most promising local treatments for colorectal liver metastases. However, tumor progression after RFA still severely affects patient prognosis, and its molecular mechanisms remain to be further explored. Here, we show that heat-stressed residual tumor cells following insufficient RFA (iRFA) can lead to lung metastases. Specific Cd177

Indexed as

Colorectal NeoplasmsLung NeoplasmsNeoplasm, ResidualNeutrophilsRadiofrequency AblationReceptors, Cell SurfaceAnimalsCell Line, TumorChemokine CXCL5Extracellular TrapsFemaleGPI-Linked ProteinsHumansIsoantigensLiver NeoplasmsMaleCD177 protein, humanChemokine CXCL5GPI-Linked ProteinsIsoantigensReceptors, Cell Surface

Identifiers

PMID41330923
PMCPMC12780263

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.